Beyond size, ionization state, and lipophilicity: Influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds

Journal of Medicinal Chemistry

Volumn 55, Issue 8, 2012, Pages 3667-3677

  Yang, Yidong ^a,b   Engkvist, Ola ^a   Llinàs, Antonio ^a   Chen, Hongming ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b Crown Bioscience Inc   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG DETERMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TOXICITY; IONIZATION; LIPOPHILICITY; MOLECULAR SIZE; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING;

BLOOD PROTEINS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CYTOCHROME P-450 CYP3A; DRUG TOXICITY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LIPID METABOLISM; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; SOLUBILITY;

EID: 84860267055     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201548z     Document Type: Article

References (56)

1. Kennedy, T. Managing the drug discovery/development interface Drug Discovery Today 1997, 2, 436-444 (Pubitemid 27387353)
2. Kubinyi, H. Drug research: myths, hype and reality Nat. Rev. Drug Discovery 2003, 2, 665-668 (Pubitemid 37368830)
3. Schuster, D.; Laggner, C.; Langer, T. Why drugs fail-a study on side effects in new chemical entities Curr. Pharm. Des. 2005, 11, 3545-3559 (Pubitemid 41300759)
4. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004, 3, 711-716
5. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new estimates of drug development costs J. Health Econ. 2003, 22, 151-185 (Pubitemid 36279392)
6. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 (Pubitemid 27046991)
7. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834 (Pubitemid 351304691)
8. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 (Pubitemid 350042396)
9. Waring, M. J. Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower log D limits based on permeability Bioorg. Med. Chem. Lett. 2009, 19, 2844-2851
10. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 2003, 46, 1250-1256 (Pubitemid 36428230)
11. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 2008, 18, 4872-4875
12. Waring, M. J.; Johnstone, C. A quantitative assessment of hERG liability as a function of lipophilicity Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764
13. Hill, A. P.; Young, R. J. Getting physical in drug discovery: a contemparary perspective on solubility and hydrophobicity Drug Discovery Today 2010, 15, 648-655
14. Ritchie, T. J.; Macdonald, S. J. F. The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discovery Today 2009, 14, 1011-1020
15. Ritchie, T. J.; Macdonald, S. J. F.; Young, R. J.; Pickett, S. D. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types Drug Discovery Today 2011, 16, 164-171
16. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
17. Yan, A.; Gasteiger, J. Prediction of aqueous solubility of organic compounds by topological descriptors QSAR Comb. Sci. 2003, 22, 821-829 (Pubitemid 38031196)
18. Leeson, P. D.; St-Gallay, S. A.; Wenlock, M. C. Impact of ion class and time on oral drug molecular properties Med. Chem. Commun. 2011, 2, 91-105
19. Yang, Y.; Chen, H.; Nilsson, I.; Muresan, S.; Engkvist, O. Investigation of the relationship between topology and selectivity for druglike molecules J. Med. Chem. 2010, 53, 7709-7714
20. Ishikawa, M.; Hashimoto, J. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry J. Med. Chem. 2011, 54, 1539-1554
21. Lu, J. J.; Crimin, K.; Goodwin, J. T.; Crivori, P.; Orrenius, C.; Xing, L.; Tandler, P. J.; Vidmar, T. J.; Amore, B. M.; Wilson, A. G. E.; Stouten, P. F. W.; Burton, P. S. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat J. Med. Chem. 2004, 47, 6104-6107 (Pubitemid 39507351)
22. Prentis, R. A.; Lis, Y.; Walker, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985) Br. J. Clin. Pharmacol. 1988, 25, 387-396
23. Hansen, N. T.; Kouskoumvekaki, I.; Jorgensen, F. S.; Brunak, S.; Jonsdottir, S. O. Prediction of pH-dependent aqueous solubility of druglike molecules J. Chem. Inf. Model. 2006, 46, 2601-2609 (Pubitemid 46008131)
24. Delaney, J. S. ESOL: estimating aqueous solubility directly from molecular structure J. Chem. Inf. Comput. Sci. 2004, 44, 1000-1005
25. Ran, Y.; Yalkowsky, S. H. Prediction of drug solubility by the general solubility equation (GSE) J. Chem. Inf. Comput. Sci. 2001, 41, 354-357 (Pubitemid 32408650)
26. Ran, Y.; He, Y.; Yang, G.; Johnson, J. L. H.; Yalkowsky, S. H. Estimation of aqueous solubility of organic compounds by using the general solubility equation Chemosphere 2002, 48, 487-509.29
27. Sanghvi, T.; Jain, N.; Yang, G.; Yalkowsky, S. H. Estimation of aqueous solubility by the general solubility equation (GSE) the easy way QSAR Comb. Sci. 2003, 22, 258-262 (Pubitemid 36723089)
28. Johnson, S. R.; Chen, X. Q; Murphy, D.; Gudmundsson, O. A computational model for the prediction of aqueous solubility that includes crystal packing, intrinsic solubility, and ionization effects Mol. Pharmaceutics 2007, 4, 513-523 (Pubitemid 47310162)
29. Karthikeyan, M.; Glen, R. C.; Bender, A. General melting point prediction based on a diverse compound data set and artificial neural networks J. Chem. Inf. Model. 2005, 45, 581-590 (Pubitemid 40795164)
30. Yee, S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth Pharm. Res. 1997, 14, 763-766 (Pubitemid 27281671)
31. Camenisch, G.; Alsenz, J.; van de Waterbeemd, H.; Folkers, G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight Eur. J. Pharm. Sci. 1998, 6, 313-319 (Pubitemid 28468539)
32. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Raevsky, O. A. Estimation of Caco-2 cell permeability using calculated molecular descriptors Quant. Struct.-Act. Relat. 1996, 15, 480-490 (Pubitemid 27023202)
33. Bergström, C. A. S.; Strafford, M.; Lazorova, L.; Avdeef, A.; Luthman, K.; Artursson, P. Absorption classification of oral drugs based on molecular surface properties J. Med. Chem. 2003, 46, 558-570 (Pubitemid 36182757)
34. Liu, X.; Chen, C.; Hop, C. E. Do we need to optimize plasma protein and tissue binding in drug discovery? Curr. Top. Med. Chem. 2011, 11, 450-466
35. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-939
36. Rodgers, S. L.; Davis, A. M.; van de Waterbeemd, H. Time-series QSAR analysis of human plasma protein binding data QSAR Comb. Sci. 2007, 26, 511-521 (Pubitemid 46942331)
37. Valko, K.; Nunhuck, S.; Bevan, C.; Abraham, M. H.; Reynolds, D. P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity J. Pharm. Sci. 2003, 92, 2236-2248 (Pubitemid 37356697)
38. Colmenarejo, G.; Alvarez-Pedraglio, A.; Lavandera, J.-L. Cheminformatic models to predict binding affinities to Human serum albumin J. Med. Chem. 2001, 44, 4370-4378 (Pubitemid 33131662)
39. Lobell, M.; Sivarajah, V. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values Mol. Diversity 2003, 7, 69-87 (Pubitemid 38095175)
40. Yamazaki, K.; Kanaoka, M. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds J. Pharm. Sci. 2004, 93, 1480-1494 (Pubitemid 38725020)
41. Saiakhov, R.; Stefan, L.; Klopman, G. Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs Perspect. Drug Discovery Des. 2000, 19, 133-155
42. Viskin, S. Long QT syndromes and torsade de pointes Lancet 1999, 354, 1625-1633 (Pubitemid 29515963)
43. Aptula, A. O.; Cronin, M. T. D. Prediction of hERG K+ blocking potency: application of structural knowledge SAR QSAR Environ. Res. 2004, 15, 399-411 (Pubitemid 39474438)
44. Ekins, S.; Crumb, W. J.; Sarazan, R. D.; Wikel, J. H.; Wrighton, S. A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel J. Pharmacol. Exp. Ther. 2002, 301, 427-434 (Pubitemid 34429951)
45. Keserü, G. M. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods Bioorg. Med. Chem. Lett. 2003, 13, 2773-2775 (Pubitemid 36851568)
46. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J. Pharmacol. Exp. Ther. 1994, 270, 414-423 (Pubitemid 24229655)
47. Guengerich, F. P. CYTOCHROME P-450 3A4: regulation and role in drug metabolism Annu. Rev. Pharmacol. Toxicol. 1999, 39, 1-17 (Pubitemid 29222549)
48. Bruneau, P. Search for predictive generic model of aqueous solubility using bayesian neural nets J. Chem. Inf. Comput. Sci. 2001, 41, 1605-1616
49. Neuhoff, S.; Ungell, A.-L.; Zamora, I.; Artursson, P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions Pharm. Res. 2003, 20, 1141-1148 (Pubitemid 36951837)
50. Fessey, R. E.; Austin, R. P.; Barton, P.; Davis, A. M.; Wenlock, M. C. The role of plasma protein binding in drug discovery. In Pharmacokinetic Profiling in Drug Research, 1 st ed.; Testa, B.; Krämer, S. D.; Wunderlie-Allenspach, H.; Folkers, G., Eds.; Verlag Helvetica Chimica Acta: Zurich, Switzerland, 2006; pp 119-141.
51. TM HT: a new high-throughput electrophysiology measurement platform J. Biomol. Screening 2003, 8, 50-64
52. Gleeson, M.; Davis, A.; Chohan, K.; Paine, S.; Boyer, S.; Gavaghan, C.; Arnby, C.; Kankkonen, C.; Albertson, N. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models J. Comput.-Aided Mol. Des. 2007, 21, 559-573 (Pubitemid 50005007)
53. BioByte ClogP, version 4.3, Claremont, CA.
54. Pipeline Pilot, version 7.5, Accelrys, San Diego, CA.
55. Wilcoxon, F. Individual comparisons by ranking methods Biometrics Bull. 1945, 1, 80-83
56. JMP, version 7, SAS Institute Inc., Cary, NC.